Browse Category

NYSE:DBI News 9 December 2025

Biggest Stock Gainers Today (December 9, 2025): AFJK, NCPL, XCUR, ALEX and DBI Lead the After‑Bell Rally

Biggest Stock Gainers Today (December 9, 2025): AFJK, NCPL, XCUR, ALEX and DBI Lead the After‑Bell Rally

U.S. stocks ended Tuesday’s session mostly flat ahead of the Federal Reserve’s final policy decision of 2025, but under the surface the tape was anything but quiet. While the S&P 500 slipped roughly 0.02%, the Dow fell about 0.32% and the Nasdaq 100 edged up around 0.18%, a pack of small‑ and mid‑cap names posted spectacular double‑ and triple‑digit gains. StockAnalysis+1 Much of the action clustered in thinly traded microcaps reacting to very specific catalysts: SPAC deadline extensions, biotech trial results, earnings surprises and take‑private deals. Here’s your final, after‑the‑bell roundup of the biggest stock gainers in the U.S. market

Stock Market Today

Disney stock ends week higher after Friday bounce — what to watch for DIS next week

Disney stock ends week higher after Friday bounce — what to watch for DIS next week

7 February 2026
Disney shares closed up 3.6% at $108.70 Friday, recovering from earlier losses as U.S. stocks rallied and the Dow topped 50,000. Investors are watching Super Bowl streaming economics and Disney’s CEO transition, with Josh D’Amaro set to take over at the March 18 meeting. Disney reported quarterly revenue of $25.98 billion and adjusted EPS of $1.63, while segment operating income fell 9% to $4.6 billion.
Novo Nordisk stock: Class B shares face Monday test after FDA squeeze forces Hims to pull $49 Wegovy copycat

Novo Nordisk stock: Class B shares face Monday test after FDA squeeze forces Hims to pull $49 Wegovy copycat

7 February 2026
Novo Nordisk Class B shares closed up 5.3% at 295.50 Danish crowns in Copenhagen after Hims & Hers said it would stop offering a compounded pill version of Wegovy following U.S. regulatory warnings. The move came after Novo called the Hims product “illegal mass compounding” and threatened legal action. Shares had fallen nearly 8% Thursday after Hims launched the pill. Trading resumes Monday.
Go toTop